Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Use of Rivaroxaban for Prophylaxis of Superficial Venous Thrombosis in Klippel-Trenaunay- Weber Syndrome - Case Report and Systematic Review

Hina Qamar, MBBS, Cynthia Wu, MD

Blood (2015) 126 (23): 4736.

https://doi.org/10.1182/blood.V126.23.4736.4736

Published: 2015

Journal Articles

Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity

Torsten Haferlach, MD, Ulrike Bacher, MD, Katja Macijewski, Vera Grossmann, MSc, Alexander Kohlmann, PhD, Tamara Alpermann, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD

Blood (2011) 118 (21): 1443.

https://doi.org/10.1182/blood.V118.21.1443.1443

Published: 2011

Journal Articles

Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups,

Ulrike Bacher, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Tamara Alpermann, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2011) 118 (21): 3583.

https://doi.org/10.1182/blood.V118.21.3583.3583

Published: 2011

Journal Articles

Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course,

Ulrike Bacher, MD, Wolfgang Kern, MD, Tamara Alpermann, Susanne Schnittger, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2011) 118 (21): 3796.

https://doi.org/10.1182/blood.V118.21.3796.3796

Published: 2011

Journal Articles

Comprehensive Investigation of 225 Patients with Myeloid Malignancies and Erythroid Hyperplasia (≥50%) Demonstrates That Acute Erythroid Leukemia (AEL, according WHO Classification 2008) Differs Significantly From MDS but Overlaps with Other AML Subtypes and Pure AEL Regarding Clinical and Genetic Features.

Ulrike Bacher, MD, Claudia Haferlach, MD, Tamara Alpermann, Susanne Schnittger, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2010) 116 (21): 1672.

https://doi.org/10.1182/blood.V116.21.1672.1672

Published: 2010

Journal Articles

Prognosis In Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Count but Depends on Cytogenetic and Molecular Genetic Parameters

Torsten Haferlach, MD, Ulrike Bacher, Tamara Alpermann, Susanne Schnittger, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD

Blood (2010) 116 (21): 2703.

https://doi.org/10.1182/blood.V116.21.2703.2703

Published: 2010

Journal Articles

VG5Q Inhibition Suppresses Proliferation of Endothelial and Cancer Cell Lines

Vi dya Bodempudi, PhD, Olivia Anna Dudek, Kaoru Terai, Arkadiusz Zbigniew Dudek, MD, PhD, FACP

Blood (2008) 112 (11): 5464.

https://doi.org/10.1182/blood.V112.11.5464.5464

Published: 2008

NARROW

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Use of Rivaroxaban for Prophylaxis of Superficial Venous Thrombosis in Klippel-Trenaunay- Weber Syndrome - Case Report and Systematic Review

Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity

Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups,

Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course,

Prognosis In Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Count but Depends on Cytogenetic and Molecular Genetic Parameters

VG5Q Inhibition Suppresses Proliferation of Endothelial and Cancer Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only